Last reviewed 2026-05-19 · How we verify

Tice Bcg (bacillus-calmette-guerin)

Tice Bcg (generic name: bacillus-calmette-guerin) is a Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC] drug developed by Pfizer. It is currently FDA-approved for Treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder, Prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR), Prophylaxis of stage TaG1 papillary tumors at high risk of tumor recurrence.

Tice BCG is a vaccine component used to treat conditions such as Tuberculosis, Non-Muscle Invasive Bladder Carcinoma, and Bladder Cancer, as indicated by ClinicalTrials.gov. It is a live vaccine, classified as a vaccine component by ChEMBL, and has been used in various clinical trials, including a Phase I open-label dose escalation trial for assessing TB immunity.

At a glance

Approved indications

• Treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder
• Prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR)
• Prophylaxis of stage TaG1 papillary tumors at high risk of tumor recurrence

Boxed warnings

• WARNING TICE ® BCG contains live, attenuated mycobacteria. Because of the potential risk for transmission, prepare, handle, and dispose of TICE ® BCG as a biohazard material (see PRECAUTIONS and DOSAGE AND ADMINISTRATION sections). BCG infections have been reported in health care workers, primarily from exposures resulting from accidental needle sticks or skin lacerations during the preparation of BCG for administration. Nosocomial infections have been reported in patients receiving parenteral drugs that were prepared in areas in which BCG was reconstituted. BCG is capable of dissemination when administered by the intravesical route, and serious infections, including fatal infections, have been reported in patients receiving intravesical BCG (see WARNINGS , PRECAUTIONS , and ADVERSE REACTIONS sections).

Common side effects

• Dysuria
• Arthritis/myalgia
• Urinary frequency
• Headache/dizziness
• Flu-like syndrome
• Urinary incontinence
• Hematuria
• Anorexia/weight loss
• Fever
• Urinary debris
• Malaise/fatigue
• Allergy

Drug interactions

• immunosuppressants and/or bone marrow depressants and/or radiation
• antimicrobial therapy
• antituberculosis drugs (e.g., isoniazid)

Key clinical trials

• Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer (PHASE2)
• A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) (PHASE1, PHASE2)
• ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG (PHASE1, PHASE2)
• Early vs Delayed Intravesical Blad-Care During BCG Therapy (NA)
• A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) (PHASE2)
• S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer (PHASE3)
• A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer (PHASE1, PHASE2)
• Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Tice Bcg CI brief — competitive landscape report
• Tice Bcg updates RSS · CI watch RSS
• Pfizer portfolio CI

Frequently asked questions about Tice Bcg

Related

• Drug class: All Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC] drugs
• Target: All drugs targeting Mycobacterium tuberculosis
• Manufacturer: Pfizer — full pipeline
• Therapeutic area: All drugs in Oncology
• Indication: Drugs for Treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder
• Indication: Drugs for Prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR)
• Indication: Drugs for Prophylaxis of stage TaG1 papillary tumors at high risk of tumor recurrence

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing